Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Abeta) for the study of Alzheimers disease.
Purity:
95.30%
CAS Number:
[1095207-05-8]
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted